Intra-operative cell salvage in urological surgery: a systematic review and meta-analysis of comparative studies

BJU International

Volumn 123, Issue 2, 2019, Pages 210-219

  Kinnear, Ned ^a,b   O'Callaghan, Michael ^c,d,e   Hennessey, Derek ^a,i   Liddell, Heath ^a,f   Newell, Bradley ^a   Bolt, John ^b   Lawrentschuk, Nathan ^a,g,h  

^a AUSTIN HEALTH   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

^f QUEEN ELIZABETH II JUBILEE HOSPITAL   (Australia)

^g PETER MACCALLUM CANCER CENTRE   (Australia)

^h OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

ⁱ CRAIGAVON AREA HOSPITAL   (United Kingdom)

Author keywords

autologous blood; autotransfusion; cell salvage; intra operative cell salvage; prostatectomy; urology

Indexed keywords

BLOOD AUTOTRANSFUSION; BLOOD CONSERVATION; COMPARATIVE STUDY; CYSTECTOMY; FOLLOW UP; HEALTH CARE COST; HUMAN; META ANALYSIS; ONCOLOGICAL PROCEDURE; OPEN SURGERY; PARTIAL NEPHRECTOMY; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTATECTOMY; RADICAL RETROPUBIC PROSTATECTOMY; REVIEW; SAFETY PROCEDURE; SYSTEMATIC REVIEW; THERAPY; TREATMENT OUTCOME; TUMOR RECURRENCE; UROLOGIC SURGERY; ADVERSE EVENT; BLADDER TUMOR; BLOOD SALVAGE; BLOOD TRANSFUSION; KIDNEY TUMOR; MALE; NEPHRECTOMY; PROSTATE TUMOR;

BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; CYSTECTOMY; HUMANS; KIDNEY NEOPLASMS; MALE; NEPHRECTOMY; OPERATIVE BLOOD SALVAGE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85060176318     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.14373     Document Type: Review

References (55)

1. Moul JW, Sun L, Wu H et al. Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. Urol Oncol 2003; 21: 447–55
2. Schmitges J, Sun M, Abdollah F et al. Blood transfusions in radical prostatectomy: a contemporary population-based analysis. Urology 2012; 79: 332–8
3. Bragayrac LA, Abbotoy D, Attwood K et al. Outcomes of minimal invasive vs open radical nephrectomy for the treatment of locally advanced renal-cell carcinoma. J Endourol 2016; 30: 871–6
4. Tang K, Xia D, Li H et al. Robotic vs. open radical cystectomy in bladder cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2014; 40: 1399–411
5. Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M. Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev 2017; (9): CD009625
6. Funk MB, Heiden M, Volkers P, Lohmann A, Keller-Stanislawski B. Evaluation of risk minimisation measures for blood components – based on reporting rates of transfusion-transmitted reactions (1997–2013). Transfus Med Hemother 2015; 42: 240–6
7. Bolton-Maggs P, Poles D. The 2016 Annual SHOT Report (2017): Serious Hazards of Transfusion; 2017. Available at: https://www.shotuk.org/wp-content/uploads/SHOT-Report-2016_web_11th-July.pdf. Accessed September 2017
8. Food and Drug Administration U. Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for FY2015 [Website]. US Food and Drug Administration; 2015. Available at: https://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM518148.pdf. [updated 11/02/2016 & 01/09/2016]
9. Sun T, Lu SF, Jin GZ. Solving shortage in a priceless market: insights from blood donation. J Health Econ 2016; 48: 149–65
10. Shander A, Hofmann A, Ozawa S, Theusinger OM, Gombotz H, Spahn DR. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010; 50: 753–65
11. Leahy MF, Trentino KM, May C, Swain SG, Chuah H, Farmer SL. Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system-wide patient blood management program. Transfusion 2017; 57: 2189–96
12. Roberts DJ, Field S, Delaney M, Bates I. Problems and approaches for blood transfusion in the developing countries. Hematol Oncol Clin North Am 2016; 30: 477–95
13. Wang YL, Jiang B, Yin FF et al. Perioperative blood transfusion promotes worse outcomes of bladder cancer after radical cystectomy: a systematic review and meta-analysis. PLoS One 2015; 10: e0130122
14. Soubra A, Zabell JR, Adejoro O, Konety BR. Effect of perioperative blood transfusion on mortality for major urologic malignancies. Clin Genitourin Cancer 2015; 13: e173–81
15. Li SL, Ye Y, Yuan XH. Association between allogeneic or autologous blood transfusion and survival in patients after radical prostatectomy: a systematic review and meta-analysis. PLoS One 2017; 12: e0171081
16. Hallet J, Hanif A, Callum J et al. The impact of perioperative iron on the use of red blood cell transfusions in gastrointestinal surgery: a systematic review and meta-analysis. Transfus Med Rev 2014; 28: 205–11
17. Ubee SS, Manikandan R, Gudimetla AR, Singh G. Cost benefits of intraoperative cell salvage in radical cystectomy. Indian J Urol 2010; 26: 196–9
18. Davies L, Brown TJ, Haynes S, Payne K, Elliott RA, McCollum C. Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model. Health Technol Assess 2006; 10: iii–iv, ix–x, 1–210
19. Prescott LS, Taylor JS, Lopez-Olivo MA et al. How low should we go: a systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. Cancer Treat Rev 2016; 46: 1–8
20. Kuppurao L, Wee M. Perioperative cell salvage. Continuing education in anaesthesia. Crit Care Pain 2010; 10: 104–8
21. Carless PA, Henry DA, Moxey AJ, O'Connell D, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010; (4): CD001888
22. Gilbert JB, Malkowicz SB, Wein AJ. Cell saver and radical retropubic prostatectomy: analysis of cost-effectiveness. Urology 1995; 46: 542–4
23. Yaw PB, Sentany M, Link WJ, Wahle WM, GGlover JL. Tumor cells carried through autotransfusion. Contraindication to intraoperative blood recovery? JAMA 1975; 231: 490–1
24. Autologous Blood Transfusions. Council on Scientific Affairs. JAMA 1986; 256: 2378–80
25. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1–34
26. Reeves BC, Deeks JJ, Higgins JPT et al. Including non-randomized studies. In Higgins J, Wells G eds, Cochrane Handbook for Systematic Reviews of Interventions 501. Chichester, UK: John Wiley & Sons, 2008: 391–432
27. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Metaanalyses. 2000. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed September 2017
28. Weider JA. Pocket Guide to Urology, 5th edn. Oakland, CA: J. Wieder Medical and Griffith Publishing, 2014
29. Bolton DM, Ta A, Bagnato M et al. Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer. World J Urol 2014; 32: 431–5
30. Ploussard G, Shariat SF, Dragomir A et al. Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time. Eur Urol 2014; 66: 361–70
31. Van Poppel H, Da Pozzo L, Albrecht W et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59: 543–52
32. Chiusano M, Finkelstein L, Mene M, Ginsberg P. Use of predeposited autologous blood plus intraoperative autotransfusion compared with use of predeposited autologous blood alone in radical retropubic prostatectomy. J Am Osteopath Assoc 1996; 96: 160–4
33. Gray CL, Amling CL, Polston GR, Powell CR, Kane CJ. Intraoperative cell salvage in radical retropubic prostatectomy. Urology 2001; 58: 740–5
34. Davis M, Sofer M, Gomez-Marin O, Bruck D, Soloway M. The use of cell salvage during radical retropubic prostatectomy: does it influence cancer recurrence? BJU Int 2003; 91: 474–6
35. Waters JH, Lee JS, Klein E, O'Hara J, Zippe C, Potter PS. Preoperative autologous donation versus cell salvage in the avoidance of allogeneic transfusion in patients undergoing radical retropubic prostatectomy. Anesth Analg 2004; 98: 537–42
36. Nieder AM, Carmack AJ, Sved PD, Kim SS, Manoharan M, Soloway MS. Intraoperative cell salvage during radical prostatectomy is not associated with greater biochemical recurrence rate. Urology 2005; 65: 730–4
37. Stoffel JT, Topjian L, Libertino JA. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy. BJU Int 2005; 96: 313–5
38. MacIvor D, Nelson J, Triulzi D. Impact of intraoperative red blood cell salvage on transfusion requirements and outcomes in radical prostatectomy. Transfusion 2009; 49: 1431–4
39. Ubee S, Kumar M, Athmanathan N, Singh G, Vesey S. Intraoperative red blood cell salvage and autologous transfusion during open radical retropubic prostatectomy: a cost-benefit analysis. Ann R Coll Surg Engl 2011; 93: 157–61
40. Gorin MA, Eldefrawy A, Manoharan M, Soloway MS. Oncologic outcomes following radical prostatectomy with intraoperative cell salvage. World J Urol 2012; 30: 379–83
41. Raval JS, Nelson JB, Woldemichael E, Triulzi DJ. Intraoperative cell salvage in radical prostatectomy does not appear to increase long-term biochemical recurrence, metastases, or mortality. Transfusion 2012; 52: 2590–3
42. Nieder AM, Manoharan M, Yang Y, Soloway MS. Intraoperative cell salvage during radical cystectomy does not affect long-term survival. Urology 2007; 69: 881–4
43. Lyon TD, Ferroni MC, Turner RM 2nd, Jones C, Jacobs BL, Davies BJ. Short-term outcomes of intraoperative cell saver transfusion during open partial nephrectomy. Urology 2015; 86: 1153–8
44. Meybohm P, Choorapoikayil S, Wessels A, Herrmann E, Zacharowski K, Spahn DR. Washed cell salvage in surgical patients: a review and meta-analysis of prospective randomized trials under PRISMA. Medicine (Baltimore) 2016; 95: e4490
45. Esper SA, Waters JH. Intra-operative cell salvage: a fresh look at the indications and contraindications. Blood Transfus 2011; 9: 139–47
46. Waters JH, Yazer M, Chen YF, Kloke J. Blood salvage and cancer surgery: a meta-analysis of available studies. Transfusion 2012; 52: 2167–73
47. Linden J. Autologous Blood Errors and Incidents (abstract). American Association of Blood Banks 47 Annual Meeting November 12–17, 1994: Transfusion; 1994. p. 28S
48. Domen RE. Adverse reactions associated with autologous blood transfusion: evaluation and incidence at a large academic hospital. Transfusion 1998; 38: 296–300
49. Leahy M, Mukhtar S. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice. Intern Med J 2012; 42: 332–8
50. Xie Y, Shen S, Zhang J, Wang W, Zheng J. The efficacy, safety and cost-effectiveness of intra-operative cell salvage in high-bleeding-risk cardiac surgery with cardiopulmonary bypass: a prospective randomized and controlled trial. Int J Med Sci 2015; 12: 322–8
51. Solomon L, von Rahden RP, Allorto NL. Intra-operative cell salvage in South Africa: feasible, beneficial and economical. S Afr Med J 2013; 103: 754–7
52. Chinkhumba J. Economics of blood screening: in search of an optimal blood screening strategy. Trop Doct 2006; 36: 32–4
53. Jacobi K, Walther A, Kühn R, Dworak O, Neidhardt B, Rügheimer E. [Advantages and limitations of intraoperative mechanical autotransfusion in al prostatectomies]. Anaesthesist 1997; 46: 101–7
54. Kumar N, Chen Y, Zaw AS et al. Use of intraoperative cell-salvage for autologous blood transfusions in metastatic spine tumour surgery: a systematic review. Lancet Oncol 2014; 15: e33–41
55. Ferroni MC, Correa AF, Lyon TD, Davies BJ, Ost MC. The use of intraoperative cell salvage in urologic oncology. Rev Urol 2017; 19: 89–96